RESUMEN
Fundamento: Até o momento, diversos escores de risco baseados em pacientes foram estabelecidos para a predição de mortalidade em pacientes com infarto do miocárdio com supradesnivelamento do segmento ST (IAMCSST). O escore de Gensini foi originalmente desenvolvido para quantificar a gravidade de doença arterial coronariana (DAC). Objetivos: Avaliar a associação entre a gravidade de DAC avaliada pelo escore de Gensini e mortalidade intra-hospitalar em pacientes com IAMCSST submetidos à intervenção coronária percutânea primária (ICP-P). Métodos: Foram incluídos 539 pacientes com IAMCSST, submetidos à ICP-P dentro das primeiras 12 horas do início dos sintomas. A gravidade da DAC foi expressa como a soma do escore de Gensini para cada lesão. Variáveis demográficas, anamnese e características clínicas dos pacientes, bem como eventos hospitalares significativos, foram obtidos de relatórios médicos. Resultados: Dos 539 pacientes, 416 (77,2%) eram do sexo masculino, e a idade média era 59,14 ± 12,68 anos. A taxa de mortalidade intra-hospitalar foi de 5,4% (29 pacientes, 16 homens). A taxa de mortalidade foi de 10,5% em pacientes do sexo feminino e 3,8% em pacientes do sexo masculino (P=0,004). Os escores de Gensini médios mostraram-se significativamente diferentes na comparação entre pacientes que sobreviveram (54,54 ± 26,34) e aqueles que foram a óbito (80,17 ± 26,51) (P = 0,001). O modelo de análise multivariada de regressão de Cox de risco proporcional revelou que o escore de Gensini (P = 0,037), o sexo feminino (P = 0,039), níveis séricos de ureia (P = 0,041), níveis de ácido úrico (P = 0,008) e FEVE (P = 0,001) estavam independentemente associados à mortalidade intra-hospitalar em pacientes com IAMCSST submetidos à ICP-P. Conclusões: O escore de Gensini está independentemente associado à mortalidade intra-hospitalar em pacientes com IAMCSST tratados com ICP-P. Portanto, o escore pode ter um papel importante na estratificação de risco de pacientes com IAMCSST
Background: To date, several validated patient-based risk scores have been established to predict mortality and morbidity in patients presenting with ST-segment elevation myocardial infarction (STEMI). The Gensini score was originally developed to quantify the severity of coronary artery disease (CAD). Objectives: We intend to assess the association between severity of CAD assessed by Gensini score and in-hospital mortality in patients with STEMI undergoing primary percutaneous coronary intervention (P-PCI). Methods: A total of 539 patients presenting with acute STEMI, who underwent P-PCI within the first 12 hours from the onset of symptoms, were included. The severity of CAD was expressed as the sum of the Gensini scores for each lesion. Patients' demographic variables, medical histories and clinical features, as well as in hospital major adverse events were obtained from the medical reports. Results: Of these 539 patients, 416 (77.2%) were male and mean age was 59.14 ± 12.68 years. In-hospital mortality rate was 5.4% (29 patients; 16 men). Mortality rate was 10.5% in female patients and 3.8% in males (P = 0.004). Mean Gensini scores were significantly different in the comparison between patients who survived (54.54 ± 26.34) and those who died (80.17 ± 26.51) (P = 0.001). The multivariable Cox proportional hazards regression analysis model revealed that the Gensini score (P = 0.037), female gender (P = 0.039), serum urea levels (P = 0.041), uric acid levels (P = 0.008) and LVEF (P = 0.001) were independently associated with in-hospital mortality in patients with STEMI undergoing P-PCI. Conclusion: The Gensini score is independently associated with in-hospital mortality in STEMI patients treated with P-PCI. Therefore, it might play an important role in risk stratification of STEMI patients
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Interpretación Estadística de Datos , Mortalidad Hospitalaria , Infarto del Miocardio , Intervención Coronaria Percutánea/métodos , Angiografía Coronaria/métodos , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/diagnóstico , Análisis Multivariante , Estudios Retrospectivos , Factores de RiesgoRESUMEN
BACKGROUND: Visfatin is a proinflammatory and insulin-mimetic adipokine contributing to whole body glucose and lipid metabolism. Studies to date are conflicting regarding the relationship between visfatin and non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the relationship of circulating visfatin with NAFLD. MATERIAL AND METHODS: The study included 114 NAFLD patients and 60 healthy non-diabetic controls. Plasma visfatin, adiponectin, tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) levels were measured by ELISA. High sensitive C-reactive protein (hsCRP) levels were measured by immunoturbidimetric fixed rate method. Insulin sensitivity determined by homeostasis model assessment (HOMA-IR) index. RESULTS: TNF-α, IL-6 and hsCRP levels were higher and, Adiponectin levels were lower in NAFLD group when compared to healthy controls (p < 0.001, for all). However, no difference was found regarding to visfatin levels between two groups. Different histologic subgroups of NAFLD had a significantly higher TNF-α, IL-6 and hsCRP, and lower adiponectin levels than those with controls (p < 0.001, for all). On the other hand, no statistically significant difference was found regarding to visfatin levels among different histologic groups. Visfatin was found to be negatively correlated with TNF-α (r = -0.236, p = 0.011) in NAFLD group. However, no association was found between visfatin and histological findings. CONCLUSION: Our findings show that plasma visfatin levels are not altered in the early stages of NAFLD. However, it is inversely associated with TNF-α. These findings suggest a role for visfatin in protection against liver injury in this widespread disease.